Buyout gets Wedbush endorsement.

[jayfish101]

Wedbush has added Geron (NASDAQ:GERN) to its Best Ideas List, a recent sell-off in shares
and its “high acquisition potential.”
The investment bank said it believes Geron shares have been “unfairly sold off” in the wake of an
FDA decision to grant a standard review with an advisory panel meeting for its drug candidate
imetelstat in the treatment of low-risk myelodysplastic syndrome. The agency is expected to make
a decision on whether to approve the product by June 16, 2024.
More on Geron
Comments Sort by
Wedbush said that it hasn’t changed its market assumptions for the drug “given its clear value
proposition.” It added that while it sees a “catalyst gap” in the near-term, it also sees “high
acquisition potential given the validated market and option upside in myelofibrosis.
Wedbush noted that Geron is expected to report interim Phase 3 data for myelofibrosis in the first
half of 2025.